Sex- and age-specific associations between cardiometabolic risk and white matter brain age in the UK Biobank cohort

Sivaniya Subramaniapillai\textsuperscript{a,b}, Sana Suri\textsuperscript{c,d}, Claudia Barth\textsuperscript{e,f}, Ivan I. Maximov\textsuperscript{e,g,h}, Irene Voldsbek\textsuperscript{e,i}, Dennis van der Meer\textsuperscript{e}, Tiiril P. Gurholt\textsuperscript{e}, Dani Beck\textsuperscript{e,f,g}, Bogdan Draganski\textsuperscript{a,j}, Ole A. Andreassen\textsuperscript{e,k}, Klaus P. Ebmeier\textsuperscript{e}, Lars T. Westlye\textsuperscript{e,g,k}, Ann-Marie G. de Lange\textsuperscript{a,c,g}

\textsuperscript{a}LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
\textsuperscript{b}Dept. of Psychology, Faculty of Science, McGill University, Montreal, Canada
\textsuperscript{c}Dept. of Psychiatry, University of Oxford, Oxford, UK
\textsuperscript{d}Wellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK
\textsuperscript{e}Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway
\textsuperscript{f}Dept. of Psychiatriy, Diakonhjemmet Hospital, Oslo, Norway
\textsuperscript{g}Dept. of Psychology, University of Oslo, Oslo, Norway
\textsuperscript{h}Dept. of Health and Functioning, Western Norway University of Applied Sciences, Bergen, Norway
\textsuperscript{i}School of Mental Health and Neuroscience, Faculty of Health Medicine and Life Sciences, Maastricht University, The Netherlands
\textsuperscript{j}Dept. of Neurology, Max Placek Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
\textsuperscript{k}KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway

Abstract: Cardiometabolic risk factors (CMRs) are associated with accelerated brain aging and increased risk for sex-dimorphic illnesses such as Alzheimer’s Disease (AD). Yet, it is unknown how CMRs interact with sex and apolipoprotein E-ε4 (APOE4), a known genetic risk factor for AD, to influence brain age across different life stages. Using age prediction based on multi-shell diffusion-weighted imaging data in 21,308 UK Biobank participants, we investigated whether associations between white matter Brain Age Gap (BAG) and body mass index (BMI), waist-to-hip ratio (WHR), body fat percentage (BF%), and APOE4 status varied i) between males and females, ii) according to age at menopause in females, and iii) across different age groups in males and females. We report sex differences in associations between BAG and all three CMRs, with stronger positive associations among males compared to females. Higher BAG (older brain age relative to chronological age) was associated with greater BMI, WHR, and BF% in males, whereas in females, higher BAG was associated with greater WHR, but not BMI and BF%. These divergent associations were most prominent within the oldest group of females (66-81yrs), where higher BF% was linked to lower BAG (younger brain age relative to chronological age). Earlier menopause transition was associated with higher BAG, but no interactions were found with CMRs. APOE4 status was not significantly associated with BAG, and no significant interactions with CMRs were found. In conclusion, the findings point to sex- and age-specific associations between body fat composition and brain age. Incorporating sex as a factor of interest in studies addressing cardiometabolic risk may promote sex-specific precision medicine, consequently improving health care for both males and females.

Keywords: Brain age; Sex differences; APOE genetic risk; Cardiometabolic health; Menopause

*Author correspondence: sivaniya.subramaniapillai@mail.mcgill.ca; ann-marie.de-lange@chuv.ch
1. Introduction

Cardiometabolic risk factors (CMRs) such as obesity are associated with adverse health outcomes including accelerated brain aging [1] and increased risk for Alzheimer’s disease (AD) [2, 3]. The impact of both CMRs and genetic risk for AD, such as apolipoprotein E-ε4 (APOE4), are known to differ between males and females [4, 5, 6, 7, 8, 9]. Yet, it is unknown whether these risk factors interact in sex-specific ways to influence brain health across different age periods or endocrine life stages. While males experience greater incidence and prevalence of cardiometabolic disease in early midlife, the greatest risk of cardiometabolic disease in females is observed up to ten years later, coinciding with the menopausal transition [10, 11]. Post menopause, female APOE4 carriers are also at greater AD risk than their male counterparts [8, 9], but it is unknown whether a reduction in neuroprotective ovarian hormones, combined with an elevated cardiometabolic and genetic risk profile, may accelerate brain aging and subsequent AD risk in females compared to males. Investigating how CMRs interact with APOE genotype to influence the brain at different life stages, whether age- or menopause-related, may thus clarify sex-specific risk profiles for accelerated brain aging and illuminate critical periods for preventive interventions.

Poor cardiometabolic health is associated with changes in brain microvasculature, which may be reflected in magnetic resonance imaging (MRI)-derived indices of white matter (WM) microstructure [12]. CMRs such as adiposity, hypertension, smoking, and diabetes have been associated with lower fractional anisotropy [13, 14, 15], lower myelin and iron content [16], and greater WM hyperintensity (WMH) burden [4, 17, 18, 19, 20, 21] in healthy older adults. Although females usually have higher volumes of WMH than males [20, 22, 23, 24, 25], extensive literature indicates that males with CMRs (adiposity, hypertension, diabetes, atherosclerosis) are more likely to develop WMH compared to females with similar levels of risk [4, 7, 26, 27, 28]. Hence, cardiometabolic health may influence WM microstructure differently in males and females, and risk profiles may also vary with age. Despite the consensus that high blood pressure and cholesterol levels are associated with accelerated brain aging and elevated dementia risk [29, 30, 31], the role of body fat is inconclusive [32, 33]. While mixed findings may be a result of selection or survivor bias [34, 35, 36, 37], or variation in
body fat indices used across studies (e.g., body mass index (BMI) versus waist-to-hip ratio (WHR) or body fat percentage (BF%)) [38, 39, 40, 41], they could also reflect a variable role of body composition throughout the lifespan. For example, one study found that BMI had a positive association with dementia risk when measured >20 years before dementia diagnosis, and a negative association when measured <10 years before dementia diagnosis [42]. Low BMI at later life stages may indicate frailty, sarcopenia (muscle loss), or preclinical dementia [43, 44, 45, 46]. Hence, while high BMI in mid-adulthood may largely reflect obesity, higher BMI in senescence may reflect overall physical fitness or lack of degenerative diseases. Furthermore, body fat may act as a source of estrogen in post-menopausal females [47], potentially protecting against WM decline [48]. However, only a few studies have tried to disentangle the role of body fat composition in endocrine versus chronological aging [49, 50]. Since risk profiles for adverse brain health may vary by sex across certain life stages, it is relevant to investigate specific age windows at which CMRs may have sex- and genotype-specific effects on the brain.

One strategy for detecting atypical brain aging, particularly if it does not involve visible pathognomonic hallmarks of degenerative brain disease, is to use machine learning to predict an individual’s age based on neuroimaging-derived measures [51, 52, 53]. Brain Age Gap (BAG) provides a measure of deviation from expected age trajectories, and has been used to identify differences in patients with neurological and psychiatric disorders relative to healthy controls [54, 53, 55, 56, 57, 58], as well as predicting future dementia risk [59] and prognosis [60, 61, 62, 63]. While individual variation in BAG reflects a combination of genetic and environmental factors [53, 64, 65], clinical studies indicate that an older ‘brain age’ relative to what is expected for an individual’s chronological age (i.e., positive BAG) may in part reflect accelerated neural aging processes [53, 54, 55, 56, 57, 66, 67]. Positive BAG values have also been associated with negative outcomes in population-based studies, including cardiovascular risk, cognitive impairments, and dementia risk [59, 61, 62, 63, 68, 69, 70, 71]. Previous studies have shown accurate age prediction based on diffusion-weighted imaging measures [72, 73, 74, 75], as well as associations between WM BAG and CMRs [1, 76]. However, these previous studies did not assess sex-specific effects, or whether CMRs interact with APOE


genotype to influence WM BAG during certain life phases.

In this study, we examined the associations between WM BAG and key CMRs, including BMI, WHR, and BF% [77, 78, 79], and APOE4 status in males (N = 10,605) and females (N = 10,703). We further assessed whether these risk factors had salient effects in middle age (44-55yrs) and different stages of older adulthood (56-65yrs and 66-82yrs) [80, 81, 82]. Participants’ brain ages were computed using a prediction model based on WM measures derived from three diffusion imaging modes: diffusion tensor imaging (DTI) [83], diffusional kurtosis imaging (DKI) [84], and WM tract integrity (WMTI) [85]. While DTI is commonly used to estimate WM indices that are highly sensitive to age [73, 86, 87, 88], biophysical diffusion models such as WMTI [85], which is derived from DKI [84], may more accurately capture WM tissue structure complexity [84, 89], thus providing greater biological specificity [90]. Given previous work indicating structural and functional sex differences in the human brain [91, 92, 93, 94], the diffusion metrics were used as input features to three separate prediction models; 1) mixed-sex, 2) female only, and 3) male only, in order to improve the accuracy of the sex-specific analyses [53, 95, 96]. We used linear regression models to assess whether associations between BAG and BMI, WHR, BF%, and APOE genotype varied i) between males and females, ii) according to age at menopause in females, and iii) across different age groups in males and females.

2. Methods and Materials

2.1. Sample characteristics

The initial sample was drawn from the UK Biobank cohort (www.ukbiobank.ac.uk), and included 39,232 participants with diffusion-weighted imaging and demographic data. We excluded 3,379 participants with diagnosed brain disorders based on ICD10 (chapter V and VI, field F; mental and behavioural disorders, including F00 - F03 for Alzheimer’s disease and dementia, and F06.7 ‘Mild cognitive disorder’, and field G; diseases of the nervous system, including inflammatory and neurodegenerative diseases (except G55-59; “Nerve, nerve root and plexus disorders”). Diagnostic details are provided in the UK Biobank online resources (http://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=41270), and in the ICD10
diagnostic manual (https://www.who.int/classifications/icd/icdonlineversions). In addition, 113 participants were excluded based on MRI outliers (see section 2.2), leaving a total of 35,740 participants with diffusion-weighted imaging data that were included in the brain age models. Only participants with complete data on demographic factors, APOE genotype, BMI, WHR, and BF% from the MRI assessment time point were included in the subsequent analyses, yielding a final sample of 21,308 (male = 10,605, female = 10,703). Sample demographics are provided in Table 1. Sex of participants refers to binary data on biological sex acquired from the NHS registry at recruitment, but in some cases updated by the participant (see https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=31).

Table 1: Sample demographics. Mean ± standard deviation (SD) and ranges for age, body mass index (BMI), waist-to-hip ratio (WHR), and body fat percentage (BF%), and % in each group for ethnic background, education, assessment location, and APOE4 status. GCSE = General Certificate of Secondary Education, NVQ = National Vocational Qualification. KW = Kruskal-Wallis, $X^2$ = chi-squared test.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Male</th>
<th>Female</th>
<th>P-value</th>
<th>Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>10,605</td>
<td>10,703</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>Mean ± SD</td>
<td>64.58 ± 7.65</td>
<td>63.12 ± 7.33</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Range [years]</td>
<td>44.57 - 81.30</td>
<td>45.48 - 81.89</td>
<td></td>
</tr>
<tr>
<td>Ethnic background</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td>$X^2$</td>
</tr>
<tr>
<td>% White</td>
<td>97.33</td>
<td>97.39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Black</td>
<td>0.47</td>
<td>0.62</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Mixed</td>
<td>0.35</td>
<td>0.46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Asian</td>
<td>1.31</td>
<td>0.63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Chinese</td>
<td>0.20</td>
<td>0.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Other</td>
<td>0.34</td>
<td>0.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td>$X^2$</td>
</tr>
<tr>
<td>% University/college degree</td>
<td>50.00</td>
<td>47.81</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% A levels or equivalent</td>
<td>12.08</td>
<td>15.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% O levels/GCSE or equivalent</td>
<td>17.06</td>
<td>20.41</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% NVQ or equivalent</td>
<td>11.32</td>
<td>6.67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Professional qualification</td>
<td>3.92</td>
<td>5.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% None of the above</td>
<td>5.62</td>
<td>4.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment location (N)</td>
<td></td>
<td></td>
<td>0.04</td>
<td>$X^2$</td>
</tr>
<tr>
<td>Newcastle</td>
<td>1916</td>
<td>1999</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cheadle</td>
<td>7280</td>
<td>7178</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reading</td>
<td>1409</td>
<td>1526</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APOE4 status</td>
<td></td>
<td></td>
<td>0.05</td>
<td>$X^2$</td>
</tr>
<tr>
<td>% carrier</td>
<td>25.48</td>
<td>26.65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% non-carrier</td>
<td>74.52</td>
<td>73.35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>Mean ± SD</td>
<td>26.72 ± 3.60</td>
<td>25.65 ± 4.18</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>WHR</td>
<td>Mean ± SD</td>
<td>0.81 ± 0.07</td>
<td>0.80 ± 0.06</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>0.53 - 1.26</td>
<td>0.60 - 1.16</td>
<td></td>
</tr>
<tr>
<td>BF%</td>
<td>Mean ± SD</td>
<td>25.12 ± 5.47</td>
<td>35.57 ± 6.44</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>5.20 - 42.50</td>
<td>7.40 - 57.5</td>
<td></td>
</tr>
</tbody>
</table>
2.2. MRI data acquisition and processing

A detailed overview of the UK Biobank data acquisition and protocols is available in [97] and [98]. Briefly, we processed diffusion-weighted imaging data using an optimized diffusion pipeline as described in detail in [99]. We included metrics derived from DTI [83], DKI [84], and WMTI [85] as input features in the age prediction models, as described in [75]. The metrics for each model are listed in Supplementary Information (SI) section 1. The metrics were extracted based on subject-specific skeletonized images [100], and Johns Hopkins University (JHU) atlases for white matter tracts (with 0 thresholding) [101] were used to provide global mean values and regional measures for 12 tracts used in previous aging and development studies [75, 86, 87, 88]; anterior thalamic radiation, corticospinal tract, cingulate gyrus, cingulum hippocampus, forceps major, forceps minor, inferior fronto-occipital fasciculus, inferior longitudinal fasciculus, superior longitudinal fasciculus, uncinate fasciculus, superior longitudinal fasciculus temporal, and corpus callosum. The included diffusion MRI data passed Tract-based spatial statistics (TBSS) post-processing quality control using the YTTRIUM algorithm [102], and were residualized with respect to scanning site using linear models. To remove further outliers, participants with SD ± 4 on the global mean FA measure were excluded, yielding a final sample of 35,740 participants with MRI data (male = 16,909, female = 18,831). To optimize prediction accuracy, the full MRI sample was included in the brain age models (Section 2.3), while the subsequent analyses (Section 2.5 - 2.6) included only participants with complete data on CMRs and APOE genotype (N = 21,308; Table 1).

2.3. Brain age prediction

We ran three age prediction models: 1) mixed-sex, 2) female only, and 3) male only, to obtain sex-specific BAG values [53, 95] as well as general BAG estimates based on the mixed sample. The prediction models were run using the XGBoost regression algorithm (eXtreme Gradient Boosting; https://github.com/dmlc/xgboost). XGBoost includes advanced regularisation to reduce over-fitting, and has shown superior performance in machine learning competitions [103]. Parameters were tuned in a nested cross-validation using 5 inner folds for grid search, and 10 outer folds for model validation. Feature importance rankings for each model were extracted using gain scores, which are calculated based on each feature’s contribution to each
tree in the model and thus indicate the relative contribution of each feature to the prediction. BAG values were calculated by subtracting chronological age from predicted brain age. The age and BAG distributions for each of the age prediction models are shown in SI Figure 1. To ensure that associations with the variables of interest were not driven by age-dependence in the BAG estimations [104, 105], chronological age was regressed out of the BAG values before they were used in subsequent analyses [106, 107].

2.4. APOE genotyping

Participants’ APOE genotype was extracted using the UK Biobank version 3 imputed data, which has been rigorously assessed for quality control by the UK Biobank genetics team [108]. The two APOE single-nucleotide polymorphisms - rs7412 and rs429358 [109] were used to estimate APOE genotype. APOE ɛ4 status was labelled carrier for ɛ3/ɛ4 and ɛ4/ɛ4 combinations, and non-carrier for ɛ2/ɛ2, ɛ2/ɛ3 and ɛ3/ɛ3 combinations [110]. We removed participants with the homozygous ɛ2/ɛ4 allele combination due to its ambiguity with ɛ1/ɛ3 [111, 109]. For more information on the genotyping process please refer to [108].

2.5. Cardiometabolic risk factors: BMI, WHR and BF%

CMRs included BMI (kg/m²), WHR (waist circumference / hip circumference), and BF% based on body composition by impedance measurement. All assessment procedures are described in detail in the UK Biobank protocol [112]. As compared to BMI, which is a general measure of body adiposity, BF% distinguishes fat from muscles, while WHR is a more specific measure of abdominal obesity. Participants with BMI > 40 were excluded (N = 196), since these values indicate morbid obesity and risk for serious health complications and comorbidities [113, 114]. The correlations between BMI, WHR, and BF% are shown in Figure 1, indicating shared variance corresponding to previous studies [77, 115, 116, 117, 118].
Figure 1: The matrices (top row) show the correlations (Pearson’s coefficients) between BMI, WHR, and BF% for all participants, as well as females and males separately. The scatter plots (bottom row) show the correlations for all participants with males plotted in red and females in blue.

2.6. Categorising groups based on i) age at menopause and ii) chronological age

To investigate whether associations of BAG with CMRs and APOE genotype varied according to age at menopause, we analyzed data from a subset of menopausal females who had complete information on age at menopause (N = 8,770). Based on previous studies binning age at menopause in approximately 5-year group bins [119, 120], we applied similar age at menopause (i.e., Menopause Age Group) categories to our sample using the following bins: 40-45 years, 46-50 years, 51-55 years, and 56-62 years (Table 2). Since the average age of menopause is typically around 51.5 years and perimenopause lasts on average 4 years [121] [122], we excluded females with age at menopause <40 years and >62 years from our analyses to ensure that results were not driven by outliers. We also excluded participants who had undergone a hysterectomy and/or oophorectomy before natural menopause, as these females often experience premature menopause associated with their surgery and may be at elevated risk of dementia [123]. Distributions for BMI, WHR, and BF% within each Menopause Age Group are shown in SI Figure 2.
To investigate whether effects of CMRs and *APOE* risk varied across different age groups, we categorised participants’ ages (i.e., Age Group) using the following bins: 45-55 years, 56-65 years, and 66-82 years (Table 2). The bins were selected to take the full cohort age range into account, and to enable comparisons of effects in middle-age and different stages of older adulthood in line with previous studies examining participants throughout the adult lifespan [80, 81, 82]. Distributions for BMI, WHR, and BF% within each Age Group are shown in SI Figure 2.

Table 2: Number of participants in each Menopause Age Group and each Age group, separated by sex and with % of *APOE4* carriers in brackets.

<table>
<thead>
<tr>
<th>Menopause Age Group</th>
<th>Female N (APOE4+)</th>
<th>Male N (APOE4+)</th>
</tr>
</thead>
<tbody>
<tr>
<td>40-45yrs</td>
<td>986 (27.48%)</td>
<td></td>
</tr>
<tr>
<td>46-50yrs</td>
<td>2,842 (26.39%)</td>
<td></td>
</tr>
<tr>
<td>51-55yrs</td>
<td>4,059 (27.32%)</td>
<td></td>
</tr>
<tr>
<td>56-62yrs</td>
<td>883 (25.93%)</td>
<td></td>
</tr>
</tbody>
</table>

To test if results were consistent between Menopause Age Group and Age Group bins and the continuous measures of these variables, we conducted supplementary analyses using the continuous variables of Age at Menopause and Age.
2.7. Statistical analyses

The statistical analyses were conducted using Python 3.7.6 and R version 3.5. All variables were standardized (subtracting the mean and dividing by the SD) before being entered into the analyses. \( P \)-values were corrected for multiple comparisons using false discovery rate (FDR) correction [124]. We report the \( F \)-test significance of each main effect and each interaction, as \( F \) is useful for interpreting models containing categorical variables with more than two levels. The \( F \)-statistics were generated in R by adding the Anova wrapper function to the linear model (\( lm \)) of interest.

We first determined whether there were sex differences in the effects of CMRs and \( APOE \) genotype on WM BAG, with the dependent variable representing BAG values based on the mixed-sex age prediction model (\( BAG_{ms} \)). In order to adjust for age-dependence in CMRs and \( APOE4 \) status, age was included as a covariate. The following \( lm \) was used for these analyses, with \( x \) representing each CMR (BMI, WHR, BF\%) or \( APOE4 \) status, respectively:

\[
BAG_{ms} \sim x \times Sex + Age. \quad (1)
\]

To test if interactions between sex and CMRs varied according to \( APOE4 \) status, the following \( lm \) was used with \( CMR \) representing each risk factor (BMI, WHR, BF\%):

\[
BAG_{ms} \sim CMR \times Sex \times APOE + Age. \quad (2)
\]

We then used the BAG values from the female-specific model to determine whether CMR and \( APOE \) effects on BAG varied according to age at menopause in females (Menopause Age Group). The following \( lm \) was used for these analyses, with \( BAG_{ss} \) representing BAG estimates based on the sex-specific model, and \( x \) representing each CMR or \( APOE4 \) status, respectively:

\[
BAG_{ss} \sim x \times Menopause Age Group + Age. \quad (3)
\]

To test if interactions between Menopause Age Group and CMR varied according to \( APOE \) genotype, the following \( lm \) was used with \( CMR \) representing each risk factor:

\[
BAG_{ss} \sim CMR \times Menopause Age Group \times APOE + Age. \quad (4)
\]
To determine whether effects in females and males varied across age bins, we ran analyses within each sex assessing the interactions of CMRs, APOE genotype, and Age Group on BAG. Sex-specific BAG values were used as dependent variables in the following lm, with x representing each CMR or APOE4 status, respectively:

\[ BAG_{ss} \sim x \times Age\ Group. \]  

(5)

To test if interactions between Age Group and CMRs varied according to APOE genotype, the following lm was used with CMR representing each risk factor:

\[ BAG_{ss} \sim CMR \times Age\ Group \times APOE. \]  

(6)

As a follow-up, we ran the following lm within each of the Age Groups (for each sex) adjusting for effects of age within each Age Group bin:

\[ BAG_{ss} \sim CMR \times APOE + Age. \]  

(7)

3. Results

3.1. Brain age prediction

The accuracy of the age prediction models are shown in Table 3. SI Tables 1 and 2 depict the top 10 WM features for the mixed-sex and sex-specific age predictions, with the majority of the features overlapping between the three models.

Table 3: Age prediction accuracy for the mixed-sex and sex-specific models, including average R², root mean square error (RMSE), mean absolute error (MAE), and correlations (r) between predicted and chronological age. CI = confidence interval.

<table>
<thead>
<tr>
<th>Model</th>
<th>R²</th>
<th>RMSE</th>
<th>MAE</th>
<th>r [95% CI]</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixed (N = 35,740)</td>
<td>0.51 ± 0.009 5.27 ± 0.007 4.23 ± 0.005 0.72[0.71,0.72]</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (N = 16,909)</td>
<td>0.50 ± 0.017 5.39 ± 0.115 4.34 ± 0.080 0.71[0.70,0.72]</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female (N = 18,831)</td>
<td>0.49 ± 0.015 5.28 ± 0.081 4.27 ± 0.070 0.69[0.69,0.70]</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
3.2. *Sex differences in effects of CMRs and APOE genotype on WM BAG*

To assess sex differences in the associations between BAG and BMI, WHR, BF%, and *APOE*4 status, we tested for sex-interactions as described in Section 2.7. The analyses revealed significant interaction effects of *Sex *BMI, *Sex *WHR, and *Sex *BF% on BAG, as shown in Table 4 and Figure 2. Greater WHR was associated with higher BAG (older brain age relative to chronological age) across sexes, but the effect was more prominent in males compared to females. BF% showed diverging associations, with higher values related to higher BAG in males and higher values related to lower BAG (younger brain age relative to chronological age) in females. Higher BMI values were associated with higher BAG in males, while no significant effect of BMI was seen in females. We observed no significant main effects of *APOE* genotype, and no significant interactions between *APOE* genotype and Sex or CMRs (see SI Table 3 for full results). Figure 2 shows the beta values for the BAG associations with each CMR and *APOE*4 status for both sexes, and for males and females separately. For comparison, we produced the same plot using estimates based on the sex-specific models (BAG values estimated relative to sex-specific age trajectories), as shown in SI Figure 1. The results showed similar patterns, with associations between higher BAG and greater BMI, WHR, and BF% in males, and between higher BAG and greater WHR, but not BMI and BF%, in females.

Table 4: Sex differences in the associations between Brain Age Gap and body mass index (BMI), waist-to-hip-ratio (WHR), body fat percentage (BF%), and *APOE*4 status based on formula 1 in Section 2.7. Degrees of freedom = (1, 21303).

<table>
<thead>
<tr>
<th>Interaction</th>
<th>F</th>
<th>p</th>
<th>pcorr</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex × BMI</td>
<td>29.15</td>
<td>6.76 × 10^{-8}</td>
<td>1.35 × 10^{-7}</td>
</tr>
<tr>
<td>Sex × WHR</td>
<td>11.45</td>
<td>7.2 × 10^{-4}</td>
<td>9.56 × 10^{-4}</td>
</tr>
<tr>
<td>Sex × BF%</td>
<td>43.37</td>
<td>4.65 × 10^{-11}</td>
<td>1.86 × 10^{-10}</td>
</tr>
<tr>
<td>Sex × APOE</td>
<td>0.93</td>
<td>0.34</td>
<td>0.34</td>
</tr>
</tbody>
</table>
3.3. Sex- and age-specific effects of CMRs and APOE genotype on WM BAG

To assess whether effects of CMRs and APOE status varied according to age at menopause or across specific age periods, we next performed a series of regressions testing for interactions with Menopause Age Group in females and Age Group in males and females separately, as described in Sections 2.6 and 2.7.

3.3.1. Effects of Menopause Age Group × CMRs and APOE genotype on WM BAG

In females, no interactions of CMR measures and APOE status with Menopause Age Group were found, as shown in Table 5. The results were consistent when using the continuous Age at Menopause variable, as shown in SI Table 5. Across models, there was a main effect of Menopause Age Group such that a lower age at menopause was associated with higher WM BAG (see SI Table 4 and SI Figure 2). This effect was consistent when using the continuous Age at Menopause variable in a regression model including hormone replacement therapy use, education, income, Townsend Deprivation Index, alcohol intake, physical activity, and number of childbirths in addition to age, BMI, and APOE status as covariates ($\beta = -0.036 \pm 0.010, p = 1.40 \times 10^{-4}$; see SI Section 6 for details about the covariates).
Table 5: The interaction between Menopause Age Group and body mass index (BMI), waist-to-hip-ratio (WHR), body fat percentage (BF%), and APOE4 status on Brain Age Gap in females (formula 3, Section 2.7). Degrees of freedom = (3, 8761).

<table>
<thead>
<tr>
<th>Interaction</th>
<th>F</th>
<th>p</th>
<th>pcorr</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI × Menopause Age Group</td>
<td>2.00</td>
<td>0.11</td>
<td>0.22</td>
</tr>
<tr>
<td>WHR × Menopause Age Group</td>
<td>1.50</td>
<td>0.21</td>
<td>0.28</td>
</tr>
<tr>
<td>BF% × Menopause Age Group</td>
<td>2.08</td>
<td>0.10</td>
<td>0.22</td>
</tr>
<tr>
<td>APOE × Menopause Age Group</td>
<td>0.73</td>
<td>0.53</td>
<td>0.53</td>
</tr>
</tbody>
</table>

3.3.2. Effects of Age Group × CMRs and APOE genotype on WM BAG

To assess whether effects of CMRs and APOE4 status varied across specific age periods, we applied regressions including interaction terms with Age Group as described in formula 5, Section 2.7. For both females and males, no significant effects were found for Age Group × CMR measures/APOE4 status on BAG (Table 6 and SI Table 6), indicating that the BAG associations with each CMR did not vary significantly between age groups. The results were consistent when using the continuous Age variable (SI Table 7). Figure 3 shows the associations between BAG and each CMR within each Age Group, and SI Figure 5 shows the associations grouped by APOE genotype.

Table 6: The interaction between Age Group and BMI, WHR, BF%, and APOE genotype on Brain Age Gap (formula 5, Section 2.7). Degrees of freedom = (2, 10599) and (2, 8764) for females and males, respectively.

<table>
<thead>
<tr>
<th>Interaction</th>
<th>Female</th>
<th>Male</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>F</td>
<td>p</td>
</tr>
<tr>
<td>BMI × Age Group</td>
<td>1.96</td>
<td>0.14</td>
</tr>
<tr>
<td>WHR × Age Group</td>
<td>1.68</td>
<td>0.19</td>
</tr>
<tr>
<td>BF% × Age Group</td>
<td>1.76</td>
<td>0.17</td>
</tr>
<tr>
<td>APOE × Age Group</td>
<td>0.31</td>
<td>0.73</td>
</tr>
</tbody>
</table>
Figure 3: Associations between WM BAG and cardiometabolic risk factors as well as APOE4 status within each Age Group bin (formula 7, Section 2.7). $\beta$ (y-axis) represents the beta value (slope) for each association. The error bars represent standard errors on the $\beta$. BMI = body mass index, WHR waist-to-hip ratio, BF% = body fat percentage.

While the BAG associations with each CMR were not significantly different between age groups (Table 6), the follow-up regression analyses within each age group indicated that the divergence between the associations with WHR versus BMI/BF% increased with older age in females (Figure 3; see SI Tables 8 and 9 for full results). As a post-hoc test, we estimated the differences between the WHR vs. BMI/BF% associations for females within each age group using a Z test for correlated samples, as described in SI Section 7. The results confirmed that the divergence between the BAG associations with WHR versus BMI/BF% increased with age, and was most prominent in the oldest age group (SI Table 10).
4. Discussion

This study investigated whether associations between BAG and CMRs and APOE genotype varied i) between males and females, ii) according to age at menopause in females, and iii) across different age groups in males and females. In summary, the results showed sex differences in associations between BAG and all three CMRs, with stronger positive associations among males compared to females. Higher BAG (older brain age relative to chronological age) was associated with greater BMI, WHR, and BF% in males, whereas in females, higher BAG was associated with greater WHR, but not BMI and BF%. Earlier age at menopause was linked to higher BAG in females, but no interactions were found between age at menopause and CMRs. While none of the associations between BAG and each CMR were significantly different between age groups, follow-up analyses indicated that the divergence between the WHR and BMI/BF% associations observed in females was most prominent within the oldest age group (66-81yrs). APOE4 status showed no significant main effects on BAG, no age- or age at menopause-specific effects, and no significant interactions with CMRs. The findings demonstrate sex-specific associations between body fat composition and brain age, emphasizing the importance of analyzing males and females separately in studies addressing cardiometabolic risk in aging.

The analyses including sex as an interaction term showed that all three CMRs were associated with higher BAG in males relative to females. These findings support a recent study, which revealed that males may be more vulnerable than females to white matter brain aging in the presence of greater BMI [4] and, more broadly, greater cardiometabolic burden [7, 26, 27, 28]. Furthermore, sex differences in adipose fat distribution may differentially contribute to brain age, with males more likely having fat distributed in the visceral adipose tissue surrounding the abdominal organs, while females tend to have more subcutaneous adipose tissue [125, 126]. Compared to the latter, greater visceral adipose fat distribution is associated with elevated risk of cardiometabolic disease. In females, differential effects of BF% and BMI compared to WHR were observed, with divergent associations particularly prominent in the oldest age group (66-82yrs) where lower BF% was linked to higher BAG. This could reflect that lower BF% in older females may be an indicator of frailty and preclin-
ical dementia, and/or indicate a protective role of certain sources of adipose fat in females at later ages [43, 44, 45, 48]. While our results showed that earlier menopause transition was associated with greater BAG, we found no significant interactions between age at menopause and CMRs. Further longitudinal work is required to clarify the role of adipose tissue in female brain health, and how it may relate to sex-specific factors including the menopausal transition.

The evidence for the role of endogenous estrogen exposure in neurodegeneration and AD is controversial, with some studies reporting an association between shorter reproductive span and greater dementia risk (e.g., [127], while others have found that a longer reproductive span (i.e., later age of menopause) did not confer protective effects (e.g., [128, 129, 130]. Some studies have reported genotype-specific effects, with a longer reproductive span conferring greater risk in APOE4 carriers [130], and older brain age linked to greater menopausal levels of estradiol in APOE4 carriers and lower levels in non-carriers [131]. These studies point to a possible modulatory role of estrogen exposure [132], typically having beneficial effects, but potentially becoming neurotoxic in the context of greater AD pathology [133] or diseased cell populations (i.e., ‘healthy cell’ hypothesis [134]). While future studies including detailed data about the menopausal transition (i.e., pre-, peri, post menopause) as well as specific measures of AD-related brain pathology [135] are required to test these hypotheses, our findings showed a small but significant association between earlier menopause transition and higher WM BAG in the current cohort, in line with studies linking a shorter reproductive span to risk for neurodegeneration [127, 130, 136, 137, 138, 139].

Unlike females, in which menses cessation is a marker of menopause status, males have a more gradual endocrine aging process, with no significant marker for age at andropause. Although low levels of body fat in older age may be an indicator of frailty in both sexes [43, 44], our results show that in this sample, greater WHR, BMI, and BF% were consistently linked to higher BAG in males. This corresponds with previous studies reporting negative effects of higher body fat levels on brain health in males across midlife and older ages [140, 141]. The male endocrine aging process typically involves gradual declines in testosterone levels.
Greater adipose tissue may increase levels of aromatase, an enzyme that converts testosterone to estrogen, which in males may be associated with their accelerated endocrine and consequently, brain aging process [142, 143, 144]. Therefore, while greater adipose tissue can potentially act as a source of estrogen in post-menopausal females, it can be detrimental to males, in whom this may result in reduced testosterone levels (see [144] demonstrating that the genetic architecture of testosterone contributes to sex differences in cardiometabolic traits in the UK Biobank). Importantly, increasing evidence points to the role of sex hormones in mediating cerebrovascular function, in which dysregulation is linked to cerebrovascular diseases, cognitive impairment, and dementia (see reviews by [145, 146]). Further research on the links between sex hormones and cardiometabolic factors in endocrine aging may help inform sex-specific health interventions for both males and females.

No significant effects were found for APOE genotype. This is in line with our previous study showing no effects of APOE4 status or polygenic risk for AD on grey-matter based brain age in the UK Biobank sample [131], as well as a recent UK Biobank study showing that APOE4+ genotype was associated with WM hyperintensities, but not with FA or MD in WM tracts [147]. While our age prediction was based on several diffusion models known to be sensitive to WM aging [73, 84, 89], it is possible that specific estimates of WM hyperintensities could yield APOE-sensitive CMR associations. Furthermore, a recent UK Biobank study revealed region- and metric-specific effects of age and sex on WM microstructure [148]. Although age prediction models combine a rich variety of WM characteristics into single estimates, global BAG estimates do not provide specific information about regional WM connections. Hence, future studies may aim to investigate regional and diffusion metric-specific estimates of brain aging in relation to APOE genotype and CMRs. Modality-specific BAG estimates are also relevant for identifying differences in brain tissue affected by a specific condition or disease [1, 55, 68, 72]. For example, one of our previous studies found that BMI interacted with AD risk to influence grey-matter based BAG, such that females with greater AD risk benefited more from a higher BMI [45]. While the current study focused on WM measures given their susceptibility to CMRs, future studies may aim to include several brain modalities to directly compare sex- and age-specific effects. More detailed measures
of fat distribution obtained with body MRI [76, 149, 150, 151] may also clarify the divergent associations observed in females, and provide a more complete understanding of adipose tissue distribution in relation to cardiometabolic disease [150, 152], AD risk [153], and endocrine aging processes [154]. Due to sample size restrictions in relation to our study goals of determining sex- and age-specific effects, we could not currently probe body MRI in our subgroups, but ongoing data collection of this measure from UK Biobank participants will render future analyses of these measures feasible.

Although the large UK Biobank cohort enabled us to investigate whether effects were sensitive to specific age- or age at menopause periods, the sample sizes were limited by probing variables with different subgroups (i.e., dividing our sample across sex, APOE genotype, and Menopause/Age Group levels). However, our sub-group samples (n>250) are still large compared to the majority of previous studies investigating sex- or age-specific effects on brain structure [155]. The results also highlight potential causes of mixed findings in the literature: variations in associations reported across studies could be due to not separating analyses by sex (see Figure 2), investigating samples with different age ranges (see Figure 3 and and SI Table 8), and/or the use of different CMRs. As participant re-testing of the UK Biobank baseline cohort is actively underway, our future work will aim to integrate longitudinal investigations of brain age, as the current cross-sectional analyses prevent any conclusions about causality. Longitudinal designs may also enable differentiation between age-specific effects and effects that emerge as a result of a selective attrition or survival bias [34, 35, 36, 37]. While UK Biobank provides an excellent resource of open-access population health data, the cohort is homogeneous with regard to ethnic background and education, and characterized by a ‘healthy volunteer effect’ [156], indicating that it is not representative of the general population [157]. Although the current results may not generalize to populations beyond those represented in this cohort, our findings may prompt further study into sex- and age-specific effects of cardiometabolic risk as well as endocrine aging. Lastly, since neural aging processes are multi-factorial, single risk factors can only explain parts of the individual variation. Hence, future studies may aim to go beyond investigating risk factors in isolation and adopt approaches that can model complex relationships between a variety of
gene-environment interactions and brain health in aging [158, 159].

In conclusion, this study demonstrates notable sex differences in associations between body fat indices and WM brain age, underlining the importance of stratifying samples by sex in population-based and clinical studies [160, 161, 162, 163, 164, 165]. Independent of cardiometabolic profile, earlier menopause transition was associated with higher BAG in females. Hence, considering effects of both chronological and endocrine aging may increase our understanding of sex-specific brain aging trajectories and disease prevalence [166, 167]. Given the historical lack of research into sex-specific influences on brain health and disease [96, 168, 166, 169], future studies incorporating sex as a variable of interest may provide valuable contributions to precision medicine research, consequently improving health care for both males and females.

Data availability statement

The data that support the findings of this study are available through the UK Biobank data access procedures (https://www.ukbiobank.ac.uk/researchers). Code for running the age prediction models is available at https://github.com/amdelange/brainage_women.

Acknowledgements

This research has been conducted using the UK Biobank under Application 27412. UKB has received ethics approval from the National Health Service National Research Ethics Service (ref 11/NW/0382). The work was performed on the Service for Sensitive Data (TSD) platform, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo IT-Department (USIT). Computations were also performed using resources provided by UNINETT Sigma2 – the National Infrastructure for High Performance Computing and Data Storage in Norway. While working on this study, the authors received funding from the Women in Cognitive Science-Canada (S. Subramaniapillai), NSERC Michael Smith Foreign Study Supplement (S. Subramaniapillai), Healthy Brains Healthy Lives (S. Subramaniapillai), the Alzheimer’s Society (S. Suri; 441), the Academy of Medical Sciences/the Wellcome Trust/the Government Department of Business, Energy and Industrial Strategy/the British Heart Foundation/Diabetes UK Springboard Award (S. Suri; SBF006\1078), the Research Council of Norway (L.T. Westlye; 273345, 249795, 298646, 300768, 223273; O.A. Andreassen; 223273, 283799, 2837989), the South-East Norway Regional Health Authority (L.T. Westlye; 2018076, 2019101, O.A. Andreassen; 2019-108, 2017-112),
the European Research Council under the European Union’s Horizon 2020 research and innovation programme (L.T. Westlye; 802998, O.A. Andreassen.; 847776, K.P. Ebmeier; 732592), the HDH Wills 1965 Charitable Trust (K.P. Ebmeier.; 1117747), the Leenaards Foundation (B. Draganski), and the Swiss National Science Foundation (AM.G. de Lange.; PZ00P3_193658; B. Draganski; NCCR Synapsy, project grants Nr 32003B_135679, 32003B_159780, 324730_192755, and CRSK-3_190185). The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z).

References


